NITTO DENKO Avecia, Inc. Signs Agreement to Acquire the Business of Girindus America, Inc.

NITTO DENKO Avecia, Inc. Signs Agreement to Acquire the Business of Girindus
America, Inc.

Bringing Together Two of the World's Leading Suppliers of Oligonucleotides

MILFORD, Mass., Nov. 12, 2012 (GLOBE NEWSWIRE) -- via PRWEB - NITTO DENKO
Avecia Inc. (Avecia), an industry leader in oligonucleotide manufacturing and
related development services, announces the acquisition of Girindus America
Inc.'s contract manufacturing business that serves both the oligonucleotide
and small molecule API areas. Final approval of the purchase agreement is
subject to Shareholders approval of Girindus AG. The acquisition merges two
complementary and respected firms to better serve their customers on a global
basis.

Both companies have a tradition of commitment to serving customers' needs in
the best of all possible ways. The integrated resources will provide customers
with complementary benefits in the therapeutic oligonucleotide marketplace, an
area where the companies anticipate substantial growth. The acquisition is a
further step in Nitto Denko Avecia, Inc.'s growth strategy to provide the
highest quality services and solutions that meet the current and future needs
of its oligonucleotide customers.

Avecia, which is an industry leader in the late clinical phase segment with
commercial oligo experience, will now offer customers an expanded range of
manufacturing capabilities, as well as a second manufacturing facility for
security of supply. Preclinical and Phase I customers will benefit from the
additional small scale capacity and flexibility. The acquisition of Girindus
also provides radiolabeling capabilities as well as additional analytical,
regulatory, and process development support to supplement Avecia's extensive
services offering.

[ABOUT NITTO DENKO Avecia Inc.]

NITTO DENKO Avecia Inc. is a drug development and manufacturing service
company located in Milford, MA, and is a part of Nitto Denko Corporation,
Japan's leading diversified materials manufacturer. Avecia is a recognized
leader in process development, manufacturing and related services for DNA and
RNA-based therapeutics. All services are offered, from pre-clinical testing to
post-commercial launch of innovative oligonucleotide-based therapeutics.

For additional information, please visit http://www.avecia.com

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit
http://www.prweb.com/releases/2012/11/prweb10097143.htm

CONTACT: NITTO DENKO Avecia Inc.
         Paula Lorence VP, Business Development
         OligoInfo@avecia.com
         508-532-2500